The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Open accessPublished version of a preprint
Abstract
Abstract Background Triple-negative breast cancer (TNBC) is a high-risk malignancy due to its high capacity for invasion and lack of targeted therapy. Immunotherapy continues to demonstrate efficacy in a variety of cancers, and thus may be a promising strategy for TNBC given the limited therapeutic options currently available for TNBC. In this study, we performed a comprehensive portrait of immunologic landscape of TNBC based on 2 large-scale breast cancer genomic data. Methods We compared expression levels of immune-related genes and gene-sets among TNBC, non-TNBC, and normal tissue, and within TNBCs of different genotypic or phenotypic features. Moreover, we explored the association of immune-related genes or gene-sets expression and survival prognosis in TNBC patients. Results We found that almost all analyzed immune-related gene-sets had significantly higher expression levels in TNBC than non-TNBC. These highly expressed gene-sets in TNBC included 15 immune cell type and function, human leukocyte antigen (HLA), cancer testis (CT), tumor-infiltrating lymphocytes (TILs), immune cell infiltrate, regulatory T (Treg) cells, immune checkpoint, cytokine and cytokine receptor, metastasis-promoting, pro-inflammatory and parainflammation (PI) gene-sets. Moreover, TP53-mutated , TNBC had significantly higher expression levels of the immune checkpoint, Treg, PI, and CT gene-sets, and lower expression levels of the immune cell infiltrate gene-set than TP53 -wildtype TNBC. Furthermore, we found that elevated expression of most of the immune-related genes in TNBC was associated with the ER-status, while some were associated with both ER-and HER2-status. Elevated expression of the immune-related genes in TNBC was also associated with the high tumor mutation burden (TMB) in TNBC. Finally, elevated expression of the immune-related gene-sets was likely to be associated with better survival prognosis in TNBC. Conclusions Our findings suggest that TNBC is a breast cancer subtype with particularly strong immunogenicity, and therefore could be propitious to immunotherapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Paradoxically, despite strong immunogenicity and a higher prevalence of tumor-infiltrating lymphocytes (TILs) in TNBC3, patients often progress to metastasis with poor clinical outcomes1.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Flagged first, then by citations
1 of the 69 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 279
Chen, S., Huang, M., Zhang, L., Huang, Q., Wang, Y., & Yang, L. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.12.001 · Cited by 22
Xu, Z., Ye, J., Zhang, X., Xia, P., Wen, X., Ma, J., Lin, J., & Qian, J. (2022) · Cancer Medicine · doi:10.1002/cam4.4905 · Cited by 18
Barakeh, D. H., Aljelaify, R. F., Bashawri, Y., Almutairi, A., Alqubaishi, F., Alnamnakani, M., AlMubarak, L., Naeem, A. A., AlMushawah, F., Alrashed, M. M., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27909 · Cited by 19
The Present and Future of Clinical Management in Metastatic Breast Cancer
Lin, P., & Laliotis, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195891 · Cited by 19
Yao, J., Li, S., & Wang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.781848 · Cited by 22
Self-citationGross, B., Chitphet, K., Wongrakpanich, A., Wafa, E. I., Norian, L. A., & Salem, A. K. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00347 · Cited by 18
KRAS mutations are negatively correlated with immunity in colon cancer
Fu, X., Wang, X., Duanmu, J., Li, T., & Jiang, Q. (2020) · Aging · doi:10.18632/aging.202182 · Cited by 21
Self-citationFermaintt, C. S., Peramuna, T., Cai, S., Takahashi‐Ruiz, L., Essif, J. N., Grant, C. V., O’Keefe, B. R., Mooberry, S. L., Cichewicz, R. H., & Risinger, A. L. (2021) · Cancers · doi:10.3390/cancers13112834 · Cited by 18
Zhao, B., Wang, Y., Wang, Y., Dai, C., Wang, Y., & Ma, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.557994 · Cited by 17
Association of BTLA rs1982809 polymorphism with lung cancer risk in Tunisian population
Khadhraoui, C., Kaabachi, W., Tritar, F., Daghfous, H., Hamzaoui, K., & Hamzaoui, A. (2020) · International Journal of Immunogenetics · doi:10.1111/iji.12491 · Cited by 17
Xiao, J.-F., Kua, L.-F., Ding, L., Sun, Q.-Y., Myint, K. N., Chia, X.-R., Venkatachalam, N., Loh, X., Duex, J. E., Neang, V., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0402 · Cited by 16
Sánchez-León, M. L., Jiménez‐Cortegana, C., Silva-Romeiro, S., Garnacho, C., de la Cruz‐Merino, L., García-Domínguez, D. J., Hontecillas‐Prieto, L., & Sánchez‐Margalet, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065208 · Cited by 16
Zhong, Y., Li, F., Zhang, S., Yang, Z., Ren, X., Cao, X., Xu, Y., Guo, D., Zhou, Y., Mao, F., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02917-7 · Cited by 16
Sacconi, A., Muti, P. C., Pulito, C., Urbani, G., Allegretti, M., Pellini, R., Mehterov, N. H., Ben‐David, U., Strano, S., Bossi, P., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01905-9 · Cited by 16
Wang, L., Liu, W., Liu, J., Wang, Y., Tai, J., Yin, X., & Tan, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.554138 · Cited by 16
Moving Towards Targeted Therapies for Triple-Negative Breast Cancer
Kagihara, J. A., Shagisultanova, E. I., Afghahi, A., & Diamond, J. R. (2021) · Current Breast Cancer Reports · doi:10.1007/s12609-021-00416-0 · Cited by 16
Li, C., Zhang, B., Schaafsma, E., Reuben, A., Wang, L., Turk, M. J., Zhang, J., & Cheng, C. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101121 · Cited by 15
Santis, P. D., Perrone, M., Guarini, C., Santoro, A. N., Laface, C., Carrozzo, D., Oliva, G. R., & Fedele, P. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00215 · Cited by 17
Edechi, C. A., Ikeogu, N. M., Akaluka, G. N., Terceiro, L. E. L., Machado, M., Salako, E. S., Barazandeh, A. F., Kung, S. K. P., Uzonna, J. E., & Myal, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639859 · Cited by 15
Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America
Pinto, J. A., Saravia, C. H., Flores, C. J., Araujo, J. M., Martı́nez, D., Schwarz, L. J., Casas-Lucich, A., Bravo, L., Zavaleta, J., Chuima, B., et al. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.896 · Cited by 15
Jørgensen, N., Lænkholm, A., Sækmose, S. G., Hansen, L. B., & Hviid, T. V. F. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108847 · Cited by 14
Alghamdi, R. A., & Al-Zahrani, M. H. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1221815 · Cited by 14
Shedding light on PRAME expression in dysplastic nevi: a cohort study
Innocenti, L., Scarpitta, R., Corraro, S., Ortenzi, V., Bonadio, A. G., Loggini, B., Ieso, K. D., Naccarato, A. G., Fanelli, G. N., & Scatena, C. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03720-5 · Cited by 14
Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers
Contos, G., Baca, Y., Xiu, J., Brown, J., Holloway, R., Korn, W. M., Herzog, T. J., Jones, N., & Winer, I. S. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.09.011 · Cited by 14
See, S. H. C., Smith, S. H., Finkelman, B. S., LaBoy, C., Novo, J. E., Siziopikou, K. P., & Blanco, L. Z. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154299 · Cited by 14
Nabi, R., Musarrat, F., Lima, J. C. M. P., Langohr, I. M., Chouljenko, V. N., & Kousoulas, K. G. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1199068 · Cited by 13
de Miranda, F. S., Martinez‐Marin, D., Babcock, R. L., Castro, M., Boligala, G. P., Khan, S. Y., Furr, K. L., Castro‐Piedras, I., Wagner, N., Robison, D. E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1498942 · Cited by 13
Mendoza, M. S., Romero‐Garcia, S., Lemini, C., & Prado-Garcı́a, H. (2021) · Journal of Immunology Research · doi:10.1155/2021/6668573 · Cited by 13
Gong, X., Liu, L., Xiong, J., Xing-fang, L., Xu, J., Xiao, Y., Li, J., Luo, X., Mao, D.-A., & Liu, L. (2021) · Journal of Oncology · doi:10.1155/2021/6620159 · Cited by 13
Zhu, X., Li, S., Luo, J., Ying, X., Li, Z., Wang, Y., Zhang, M., Zhang, T., Jiang, P., & Wang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.801639 · Cited by 13
Self-citationTargeting biologically specific molecules in triple negative breast cancer (TNBC)
Mir, M. A., Sofi, S., & Qayoom, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96136-3.00002-9 · Cited by 13
Analysis of multi-omics differences in left-side and right-side colon cancer
Huang, Y., Duanmu, J., Liu, Y., Yan, M., Li, T., & Jiang, Q. (2021) · PeerJ · doi:10.7717/peerj.11433 · Cited by 13
Subtyping of head and neck squamous cell cancers based on immune signatures
Song, D., Lyu, H., Feng, Q., Luo, J., Li, L., & Wang, X. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108007 · Cited by 13
Self-citationDas, R., Deb, S., & Suresh, P. K. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01892-9 · Cited by 16
TAZ facilitates breast tumor growth by promoting an immune‐suppressive tumor microenvironment
Gershoni, A., Hassin, O., Nataraj, N. B., Baruch, S., Seligman, A., Pirona, A. C., Fellus‐Alyagor, L., Salame, T. M., Mukherjee, S., Mallel, G., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13525 · Cited by 12
Zhou, Y., Zhang, L., Song, S., Xu, L., Yan, Y., Wu, H., Tong, X., & Yan, H. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.649270 · Cited by 12
Mukund, K., Veraksa, D., Frankhouser, D. E., Yang, L., Tomšič, J., Pillai, R. K., Atti, S., Mesrizadeh, Z., Schmolze, D. D., Zabaleta, J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116752 · Cited by 11
Qian, K., & Liu, Q. (2023) · Translational Breast Cancer Research · doi:10.21037/tbcr-23-17 · Cited by 10
Shatalov, P. A., Bukaeva, A. A., Михайлович, В. Е., Traspov, A. A., Багдасарова, Д. В., Леухина, И. А., Shinkarkina, A. P., Raygorodskaya, M. P., Murzaeva, A. V., Mechenici, Y. A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092213 · Cited by 10
Immunotherapeutic Strategies Targeting Breast Cancer Stem Cells
Vasileiou, M., Diamantoudis, S. C., Tsianava, C., & Nguyen, N. P. (2024) · Current Oncology · doi:10.3390/curroncol31060232 · Cited by 10
Qian, X., Tao, Y., Chen, H., Li, X., Wang, Y., Xu, X., Li, S., Chen, H., Cang, S., & Liu, Y. (2024) · Oncology Letters · doi:10.3892/ol.2024.14775 · Cited by 10
The Roles of Natural Killer Cells in Breast Cancer Pathobiology and Their Regulation by Estrogens
Byemerwa, J. K., Chang, C., & McDonnell, D. P. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf014 · Cited by 11
Management of triple-negative breast cancer in the era of novel therapies: A narrative review
Sharma, R., & Gogia, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_226_21 · Cited by 10
Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments
Abraham, M. J., Gonçalves, C., McCallum, P. A., Gupta, V., Preston, S. E. J., Huang, F., Chou, H., Gagnon, N., Johnson, N. A., Miller, W. H., et al. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01199-4 · Cited by 10
López, C., Gibert‐Ramos, A., Bosch, R., Korzyńska, A., García‐Rojo, M., Bueno, G., García-Fontgivell, J. F., Martínez, S., Fontoura, L., Navarro, A. G., et al. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.11.008 · Cited by 10
Mir, M. A., Sofi, S., & Qayoom, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96136-3.00014-5 · Cited by 9
Li, D., Tulahong, A., Uddin, M. N., Zhao, H., & Zhang, H. (2021) · Quantitative Finance and Economics · doi:10.3934/mbe.2021324 · Cited by 9
Zhang, W., Zhao, B., Xiang, Z., Wu, B. C., Zhang, X., Feng, N., & Wei, Y. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612829666221207112438 · Cited by 9
Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest
Kim, L., Coman, M., Pusztai, L., & Park, T. S. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13714-x · Cited by 9
He, Y., Liu, Z., Jiang, Z., & Wang, X. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i4.270 · Cited by 10
Self-citationMolecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
Ibragimova, M. K., Tsyganov, M. M., & Литвяков, Н. В. (2021) · Cancers · doi:10.3390/cancers13215348 · Cited by 9
Geng, H., Dong, Z., Zhang, L., Yang, C. G., Li, T., Lin, Y., Ke, S., Xia, X., Zhang, Z., Zhao, G., et al. (2022) · Cancers · doi:10.3390/cancers14133276 · Cited by 9
Wang, J., Uddin, M. N., Wang, R., Gong, Y., & Wu, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.922213 · Cited by 9
Yadav, S., Zhou, S. W., He, B., Du, Y., & Garmire, L. X. (2023) · Communications Medicine · doi:10.1038/s43856-023-00414-6 · Cited by 8
Hierarchical Clustering of Cutaneous Melanoma Based on Immunogenomic Profiling
Yu, J., Xie, M., Ge, S., Chai, P., Zhou, Y., & Ruan, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580029 · Cited by 9
Li, H., Sun, X., Zhao, Y., Zhang, C., Jiang, K., Ren, J., Xing, L., & He, M. (2023) · BMC Cancer · doi:10.1186/s12885-023-11015-w · Cited by 8
Dubner, J. L., Neugut, A. I., Joffe, M., O’Neil, D. S., Ayeni, O., Chen, W. C., Buccimazza, I., Čačala, S., Stopforth, L. W., Farrow, H. A., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(24)00376-0 · Cited by 8
Wang, X., Wang, L., & Liu, Y. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70072 · Cited by 10
Self-citationEmerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape
Xie, X., Lee, J., Iwase, T., Kai, M., & Ueno, N. T. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2077188 · Cited by 8
Pinho, M. P., Patente, T. A., Flatow, E. A., Sallusto, F., & Barbuto, J. A. M. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1607674 · Cited by 8
Chen, C., Luo, J., & Wang, X. (2022) · Medical Oncology · doi:10.1007/s12032-022-01719-7 · Cited by 9
Self-citationThe search for a TNBC vaccine: the guardian vaccine
Fines, C. B., McCarthy, H. O., & Buckley, N. E. (2025) · Cancer Biology & Therapy · doi:10.1080/15384047.2025.2472432 · Cited by 7
Xie, B., Chen, C., Cai, H., Wang, L., Chen, M., Liu, J., Wu, F., & Huang, W. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00379-7 · Cited by 7
Wang, S., Shen, Y.-C., Pan, M., Ou‐Yang, F., Liao, T.-Y., Liu, L., Rau, K.-M., Lu, L., Huang, C., Dai, M., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217912 · Cited by 7
Lu, Q., Luo, J., Tung, C.-H., Wang, X., & Zhao, Z. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01223-x · Cited by 6
Self-citationThompson, J. A., Christensen, B. C., & Marsit, C. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-23494-0 · Cited by 6
Immuno-oncology in triple-negative breast cancer
Heimes, A.-S., & Schmidt, M. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.124 · Cited by 7
Zhang, M., Lin, Y., Zeng, W., Li, Y., Yang, Y., Miao, L., Ye, Y., Jiang, K., Wang, S., & Wang, S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.790888 · Cited by 6
Makrantonakis, A.-E., Zografos, E., Gazouli, M., Dimitrakakis, K., Toutouzas, K. G., Zografos, C. G., Kalapanida, D., Tsiakou, A., Samelis, G., & Zagouri, F. (2022) · Medicina · doi:10.3390/medicina58101399 · Cited by 6
Akhouayri, L., Ostano, P., Grand, M. M., Gregnanin, I., Crivelli, F., Laurora, S., Liscia, D., Leone, F., Santoro, A., Mulè, A., et al. (2022) · Human Genomics · doi:10.1186/s40246-022-00436-6 · Cited by 6
Manoochehri, M., Hielscher, T., Borhani, N., Gerhäuser, C., Fletcher, O., Swerdlow, A. J., Ko, Y., Brauch, H. B., Brüning, T., & Hamann, U. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01196-1 · Cited by 6
Gu, H.-Y., Qu, W., Peng, H., Yu, Y., Jiang, Z.-Z., Qi, B., & Yu, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.796606 · Cited by 6
Self-citationSofroniou, M. M., & Lemmon, C. A. (2023) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2023.106478 · Cited by 6
mtPCDI: a machine learning-based prognostic model for prostate cancer recurrence
Cheng, G., Xu, J., Wang, H., Chen, J., Huang, L., Qian, Z. R., & Fan, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1430565 · Cited by 5
Integrating Genomic Information with Tumor-Immune Microenvironment in Triple-Negative Breast Cancer
Otohinoyi, D. A., Kuchi, A., Wu, J., & Hicks, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192113901 · Cited by 5
Khamwut, A., Klomkliew, P., Jumpathong, W., Kaewsapsak, P., Chanchaem, P., Sivapornnukul, P., Chantanakat, K., T‐Thienprasert, N. P., & Payungporn, S. (2023) · Biomedical Reports · doi:10.3892/br.2023.1652 · Cited by 5
Elghazawy, H. I., Bakkach, J., Helal, T., Aref, A., Kelany, M., Abdallah, L. E., Abdelbakey, F., Ali, D., Ali, D. Z., Ahmed, M. O., et al. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1317 · Cited by 5
Classification of triple-negative breast cancer based on pathway enrichment levels
Liu, Q., & Wang, X. (2023) · Medical Oncology · doi:10.1007/s12032-023-02021-w · Cited by 5
Self-citationJeon, S. H., Suh, K. J., Jung, S., Jeon, M., Jang, H. C., Kim, E.-S., Kim, S. H., Lee, K.-H., Im, S., Kim, M. H., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3283 · Cited by 4
Jiang, Z., Xu, J., Zhang, S., Lan, H., & Bao, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04957-y · Cited by 4
Self-citationLi, J., Hu, C.-J., Peng, H., & Chen, E. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1975 · Cited by 4
Zhao, J. J., Wang, R., Sun, X., Huang, K., Jin, J., Lan, L., Jian, Y., Xu, Z., Wu, H., Wang, S., et al. (2022) · Genetics Research · doi:10.1155/2022/8213723 · Cited by 4
A signature-based classification of lung adenocarcinoma that stratifies tumor immunity
Zhang, X., Jiang, D., Li, S., Zhang, X., Zheng, W., & Cheng, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023833 · Cited by 4
Chen, Z., Cao, W., Luo, J., Abdelrahman, Z., Lu, Q., Wang, H., & Wang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1191365 · Cited by 4
Self-citationSu, N. Y., Lian, W., Zhang, B., Tian, Y., Li, L., Chen, Y., Zhi, X., Zeng, T., Wu, Q., Chen, L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102420 · Cited by 3
Host–microbiome interactions in breast cancer progression and treatment response
Bautista, J., Lara-Hernández, M. E., Cruz, M. H.-D. L., Andino-Araque, V., León-Rivera, M., & López‐Cortés, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1827694 · Cited by 4
Thorner, P. S., Chong, A., Apellániz-Ruiz, M., Benlimame, N., Marrano, P. M., Brimo, F., Shuangshoti, S., Shuangshoti, S., & Foulkes, W. D. (2024) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002209 · Cited by 3
Mechanics and Synergistic Signaling of Fibronectin, Integrins, and TGF-β Isoforms
Sofroniou, M. M., & Lemmon, C. A. (2025) · Fibrosis · doi:10.70322/fibrosis.2025.10003 · Cited by 3
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: What is the Evidence?
Chok, N., & Chokr, S. (2018) · Journal of Neoplasm · doi:10.21767/2576-3903.100031 · Cited by 3
Seok, J., Ryu, C. H., Ryu, J., Kim, J. H., Lee, S.-J., Park, W. S., & Jung, Y. (2020) · Biology · doi:10.3390/biology9110387 · Cited by 3
Reclassification of Kidney Clear Cell Carcinoma Based on Immune Cell Gene-Related DNA CpG Pairs
Luo, Q., & Vögeli, T. (2021) · Biomedicines · doi:10.3390/biomedicines9020215 · Cited by 3
Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape
Huang, L., Liu, X., Li, L., Wang, L., Wu, N., & Liu, Z. (2022) · Medical Oncology · doi:10.1007/s12032-022-01690-3 · Cited by 4
Self-citationZhang, F., Zhang, M., Yuan, X. T., Tao, Y., & Wang, J. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230901143203 · Cited by 3
Identifying Diffuse Glioma Subtypes Based on Pathway Enrichment Evaluation
Feng, Q., Dong, Z., Nie, R., & Wang, X. (2024) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-024-00627-w · Cited by 3
Self-citationKoczka, K., & Nixon, N. A. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-20-58 · Cited by 4
Murillo, O. D., Petrosyan, V., LaPlante, E. L., Dobrolecki, L. E., Lewis, M. T., & Milosavljevic, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.06.498858 · Cited by 3
Jeong, Y. J., Lee, N.-R., & Oh, H. K. (2025) · Discover Oncology · doi:10.1007/s12672-025-03591-z · Cited by 2
Zambrano, Y., Mejía‐García, A., Ramírez-Mejía, J. M., Tsao, H. M., Morales-Suárez, P. D., Rey-Vargas, L., Ovalle, W. J. M., Huertas-Caro, C. A., López-Correa, P., Riaño-Moreno, J. C., et al. (2025) · Biology · doi:10.3390/biology14121706 · Cited by 2
Hosseini, M., Shahosseini, Z., Meymandi, A. R. P., Shahverdi, A. R., Faramarzi, M. A., Ghassemi, S., Hadjati, J., Yazdi, M. H., & Mirzaei, H. R. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.01.018 · Cited by 2
Mishra, R., Ademuyiwa, F. O., Yang, Y., Herndon, J. M., Li, L., Street, C., Myers, N. B., Chen, I., Zhang, X., Hagemann, I. S., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0666 · Cited by 2
Metadata
- Authors
- Liu, Z., Li, M., Jiang, Z., & Wang, X.
- Affiliations
- China Pharmaceutical University (CN)
- Corresponding author
- Wang, Xiaosheng
- Venue
- Translational Oncology
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 11
- Issue
- 2
- Pages
- 311-329
- ISSN
- 1936-5233 (ISSN-L)
- PMC
- PMC5884188
- OpenAlex
- W2766581433
- Cited by
- 275
- References
- 69
- Citations by year
- 2026: 14 · 2025: 25 · 2024: 22 · 2023: 39 · 2022: 45 · 2021: 51 · 2020: 46 · 2019: 24 · 2018: 9
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Translational Oncology (publishedVersion, cc-by-nc-nd)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- China Pharmaceutical University (2632018YX01, 3150120001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- triple-negative breast cancer, tumor immunogenicity, immune pathways, immunotherapy, breast cancer subtypes, survival prediction, genomic data analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
